| 1.29 -1.07 (-45.34%) | 09-30 14:04 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.59 | 1-year : | 5.18 |
| Resists | First : | 3.07 | Second : | 4.44 |
| Pivot price | 2.18 |
|||
| Supports | First : | 0.87 | Second : | 0.72 |
| MAs | MA(5) : | 2.02 |
MA(20) : | 2.42 |
| MA(100) : | 1.03  |
MA(250) : | 0.79 |
|
| MACD | MACD : | 0 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 23.1 |
D(3) : | 23.6 |
| RSI | RSI(14): 41.2 |
|||
| 52-week | High : | 4.44 | Low : | 0.46 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ NBY ] has closed below the lower bollinger band by 6.7%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ NBY ] is to continue within current trading range. It is unclear right now based on current values. 108.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 28 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.52 - 2.53 | 2.53 - 2.54 |
| Low: | 2.18 - 2.19 | 2.19 - 2.2 |
| Close: | 2.34 - 2.36 | 2.36 - 2.37 |
NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
Tue, 30 Sep 2025
Morning Market Movers: SPRC, VALN, NBY, And Other Gainers & Losers - RTTNews
Fri, 19 Sep 2025
NovaBay Pharma Announces Special Cash Dividend - The Globe and Mail
Sat, 06 Sep 2025
NovaBay Pharmaceuticals Faces Growth Challenges Amidst Financial Instabilities - StocksToTrade
Tue, 02 Sep 2025
NovaBay Stock: A Wild Ride or Solid Bet? - StocksToTrade
Wed, 27 Aug 2025
NovaBay Stock Surge: Buy or Wait? - timothysykes.com
Tue, 26 Aug 2025
NovaBay Pharma Announces Special Cash Dividend - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 6 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 21.2 (%) |
| Shares Short | 76 (K) |
| Shares Short P.Month | 38 (K) |
| EPS | 2.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.73 |
| Profit Margin | 33.9 % |
| Operating Margin | -57.9 % |
| Return on Assets (ttm) | -65.3 % |
| Return on Equity (ttm) | -413.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 1.11 |
| Sales Per Share | 1.68 |
| EBITDA (p.s.) | -0.97 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 3 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | 0.56 |
| PEG Ratio | 0 |
| Price to Book value | 1.77 |
| Price to Sales | 0.77 |
| Price to Cash Flow | 2.8 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|